Dr Boreham’s Crucible: FDA approval blasted this regenerative biotech higher in 2024… so what’s next?
Fresh from its landmark US regulatory approval for its stem-cell product for paediatric graft-versus-host disease (GvHD), Mesoblast plans to waste no time pursuing consent for the much bigger indications of heart disease and back pain. Other inflammatory …